Discover
FDA Drug Safety Podcasts
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity

Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
Update: 2024-01-26
Share
Description
Listen to FDA Drug Safety Podcast, FDA's preliminary evaluation has not found evidence that use of GLP-1 RAs causes suicidal thoughts/actions.
Comments
In Channel
00:00
00:00
x
0.5x
0.8x
1.0x
1.25x
1.5x
2.0x
3.0x
Sleep Timer
Off
End of Episode
5 Minutes
10 Minutes
15 Minutes
30 Minutes
45 Minutes
60 Minutes
120 Minutes



